Multiplex Serum panels for Osteoarthritis & Joint Injury

Information

  • Research Project
  • 8315240
  • ApplicationId
    8315240
  • Core Project Number
    R43AR062983
  • Full Project Number
    1R43AR062983-01
  • Serial Number
    062983
  • FOA Number
    PA-09-127
  • Sub Project Id
  • Project Start Date
    9/1/2012 - 12 years ago
  • Project End Date
    11/30/2013 - 11 years ago
  • Program Officer Name
    TYREE, BERNADETTE
  • Budget Start Date
    9/1/2012 - 12 years ago
  • Budget End Date
    11/30/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/14/2012 - 12 years ago

Multiplex Serum panels for Osteoarthritis & Joint Injury

DESCRIPTION (provided by applicant): The development of a cure for osteoarthritis, the most common cause of pain and disability in the elderly, is difficult because of a lack of good diagnostics tests, in particular for early stages of the disease. Many candidate biomarkers are in various stages of qualification. Limited amounts of precious, well characterized serum and plasma samples are available from the Osteoarthritis Initiative and several clinical trials. Validated multiplexed immunoassays would make the best use of these precious samples. However, at present, few osteoarthritis-related biomarkers assays are available in a high-throughput multiplex format. The technical objective for Phase I of this project is the development of high throughput multiplex panels for the quantitative measurement of 16 serum biomarkers relevant for osteoarthritis and joint injury. Two panels will be developed in a 96-well 10-spot format based upon MSD's high-sensitivity MULTI-ARRAY(R) electrochemiluminescence technology. Panel A will include up to ten low abundance markers and will require 25 ul of serum. Panel B will include up to ten high abundance markers and will require 1 ul of serum. After an analytical verification, a limited number of clinical samples will be tested. In Phase II, we will expand the panels to approximately 40 assays and determine biomarker concentrations in samples from an osteoarthritis clinical trial. PUBLIC HEALTH RELEVANCE: The development of a cure for osteoarthritis, the most common cause of pain and disability in the elderly, is difficult because of a lack of good diagnostics tests, in particular for early stages of the disease. The objective of this proposal is the development of blood tests that measure many potentially useful biomarkers at the same time. This will lead to better ways to determine whether a treatment is effective earlier in the treatment regimen.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    199766
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:199766\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MESO SCALE DIAGNOSTICS, LLC
  • Organization Department
  • Organization DUNS
    113033224
  • Organization City
    ROCKVILLE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    208503126
  • Organization District
    UNITED STATES